Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care by Nunes, Anthony P. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2017-12-01 
Tolerability and Effectiveness of Exenatide Once Weekly Relative 
to Basal Insulin Among Type 2 Diabetes Patients of Different 
Races in Routine Care 
Anthony P. Nunes 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Clinical Epidemiology Commons, Endocrine System Diseases Commons, Endocrinology, 
Diabetes, and Metabolism Commons, Epidemiology Commons, Health Information Technology 
Commons, and the Nutritional and Metabolic Diseases Commons 
Repository Citation 
Nunes AP, Loughlin AM, Qiao Q, Ezzy SM, Yochum L, Clifford CR, Gately RV, Dore DD, Seeger JD. (2017). 
Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes 
Patients of Different Races in Routine Care. Open Access Articles. https://doi.org/10.1007/
s13300-017-0314-z. Retrieved from https://escholarship.umassmed.edu/oapubs/3277 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
ORIGINAL RESEARCH
Tolerability and Effectiveness of Exenatide Once
Weekly Relative to Basal Insulin Among Type 2
Diabetes Patients of Different Races in Routine Care
Anthony P. Nunes . Anita M. Loughlin . Qing Qiao .
Stephen M. Ezzy . Laura Yochum . C. Robin Clifford . Robert V. Gately .
David D. Dore . John D. Seeger
Received: June 16, 2017 / Published online: October 5, 2017
 The Author(s) 2017. This article is an open access publication
ABSTRACT
Introduction: Analyses of efficacy and tolera-
bility of pharmacologic interventions are based
on clinical trials that often include predomi-
nately white populations, in part because of
challenges associated with recruitment and
retention of racial/ethnically diverse study
populations. Using real-world electronic health
record (EHR) data, we sought to evaluate the
tolerability and effectiveness of exenatide once
weekly (EQW), overall and relative to basal
insulin (BI), according to race.
Methods: Patients with type 2 diabetes initiat-
ing EQW or BI between 2012 and 2015 were
selected from the Optum EHR Research Data-
base, a system pooling data from dozens of
hospitals throughout the US. Measures of
HbA1c, weight, and body mass index (BMI)
were summarized at initiation and quarterly in
the first year afterwards. Occurrences of gas-
trointestinal (GI) symptoms and hypoglycemia
were identified by diagnostic codes and clinical
notes, and incidence rates (IR) and relative rates
(RR) were calculated.
Results: Overall, 4907 white patients (mean
age = 57 years) and 454 African American
patients (mean age = 53 years) were included.
The percent change in HbA1c from initiation
through 9–12 months was similar for white and
African American patients [EQW-White: -6.89
(95% CI: -8.29, -5.50), EQW-African Ameri-
can: -5.99 (95% CI: -10.33, -1.65), BI-White:
-4.68 (95% CI: -5.51, -3.86), BI-African
American: -3.11 (95% CI: -5.37, -0.85)]. For
EQW, percent change in weight was -1.73 (95%
CI: -2.45, -1.02) for white patients and -1.11
(95% CI: -3.02, -0.81) for African American
patients. No weight loss was observed among BI
initiators. Relative to BI initiators, EQW initia-
tors had lower rates of hypoglycemia [White RR:
0.82 (95% CI: 0.66, 1.01), African American RR:
0.59 (95% CI: 0.26, 1.34)]. GI symptoms were
increased in white EQW initiators.
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INTRODUCTION
Relative to non-Hispanic white patients, non-
white patients in the US have a disproportion-
ally elevated risk of type 2 diabetes mellitus and
type 2 diabetes mellitus related morbidity and
mortality [1–4]. It has been demonstrated that
non-white patients exhibit poorer metabolic
control relative to white patients [5, 6]. Analyses
of efficacy and tolerability of pharmacologic
interventions, including those used to treat type
2 diabetes mellitus, are based on clinical trials
that often include predominately white popu-
lations, in part because of challenges associated
with recruitment and retention of racial/ethni-
cally diverse study populations [7, 8]. Despite
the underrepresentation of non-white patients,
there is some evidence of different treatment
efficacy and tolerability according to race for
some antihyperglycemic medications [9, 10].
Indicators of tolerability, such as hypoglycemia
incidence, have been reported to be elevated in
African American patients relative to non-His-
panic white patients [10]. This observation has
been attributed to self-administered type 2 dia-
betes mellitus treatments and may be due to
differences in adherence, lower use of or access
to HbA1c testing, as well as environmental and
lifestyle factors.
Sub-optimally controlled type 2 diabetes
mellitus may require use of more intensive
treatment options, possibly including combi-
nation therapies and/or injectable antihyper-
glycemic medication. These more intensive
therapies can lead to increased treatment com-
plexity and reduced tolerability. Evidence from
randomized controlled trials has shown that
exenatide once weekly (EQW), as a later line
therapy, may have some clinical advantages
such as convenient dosing, weight loss, low
incidence of hypoglycemia, improved blood
pressure, and an improved lipid profile. How-
ever, the degree to which these advantages lead
to improved effectiveness and tolerability in
customary clinical care and among different
races is less known.
While prior studies have observed differential
type 2diabetesmellitus characteristics and type 2
diabetes mellitus treatment responses by race,
studies with real-world data have not investi-
gated race-specific differences in the tolerability
or effectiveness of EQW. In this study, we evalu-
ate the tolerability and effectiveness of EQW
among type 2 diabetes patients of different races
in routine patient care in the US, with additional
results for basal insulin (BI) provided for context.
METHODS
Data Source
The study population was drawn from Optum’s
electronic health records (EHR) database. The
EHR database is updated on a quarterly basis
and integrates records from many medical
groups and hospitals. The contributing medical
groups represent a geographically diverse
patient population within the USA. At the time
of this study, the EHR database included over
25,000 physicians and over 25 million patients,
forming a broad patient-level database of
healthcare encounters in ordinary clinical
practice. The EHR captures clinical, operational,
and financial information that physicians
record at the time of care. This information
includes diagnoses, procedures, medications
(prescribed and administered), clinical measures
(biometric and laboratory values), and clinical
notes [e.g., physician, pathology, and radiology
notes as well as notes indicating hypoglycemia
and gastrointestinal (GI) symptoms].
The data access and conduct of this study
conformed to applicable Health Insurance
Portability and Accountability Act (HIPAA)
policies. Approval of the study protocol and a
waiver of informed consent were obtained from
a central institutional review board.
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Study Design and Population
Injectable-naive patients with type 2 diabetes
mellitus who initiated either EQW or BI were
identified within the EHR data between January
2012 and January 2015, with follow-up through
March 2015. The baseline period was defined as
the 183 days (6 months) prior to the date of
study drug initiation (index date). From the
EHR data, patients with type 2 diabetes mellitus
were identified using International Classifica-
tion of Disease, Ninth Revision, Clinical Modi-
fication (ICD-9-CM) codes, and initiations of
EQW or BI (i.e., insulin glargine or insulin
detemir) were identified in the EHR data cap-
turing prescribed medications using National
Drug Codes (NDC) and drug descriptions. The
study population was limited to those who were
at least 18 years old, had at least 6 months of
available baseline data (defined as documenta-
tion of an outpatient medical visit 6 or more
months prior to study drug initiation), and had
at least one diagnosis of type 2 diabetes mellitus
(ICD-9-CM: 250.X0 or 250.X2) prior to and
including the date of the study drug initiation.
Patients with a prior diagnosis of type-1 diabetes
(ICD-9-CM: 250.X1 or 250.X3) or gestational
diabetes, or with evidence of prior dispensings
of a glucagon-like peptide 1 receptor agonist or
insulin were excluded from the study popula-
tion. Using the prescription data, the date of
cohort entry was identified as the date of first
prescription of EQW or BI meeting the study
eligibility criteria.
Propensity Score Analysis and Matching
All analyses were conducted with the use of SAS
version 9.2. Propensity matching was imple-
mented to achieve balance between EQW and
BI with respect to a large number of character-
istics [11, 12]. The propensity score model
incorporated dozens of predictors, identified in
EHR data from the baseline period, of the use of
EQW over BI. These variables included a wide
range of demographic, medical, and health care
utilization information that may have been
associated with the decision to begin one or the
other treatment. Clinical observations (i.e.,
body weight, body mass index, systolic and
diastolic blood pressure) were selected from the
EHR observation table, laboratory values [i.e.,
hemoglobin A1c (HbA1c), serum creatinine,
urine albumin/creatinine ratio (ACR), total
cholesterol (TC), high density lipoprotein
(HDL) cholesterol, low density lipoprotein
(LDL) cholesterol, and triglycerides (TG)] were
selected from the EHR laboratory table. For
clinical observation and laboratory values, the
last available value available occurring in the
baseline period was selected to represent status
at initiation of therapy; if no value was observed
during baseline, the value was multiply-im-
puted (5 imputations) using fully conditional
specification methods (FCS) [13]. Estimated
glomerular filtration rate (eGFR) was calculated
from serum creatinine, sex and race variables
using the Chronic Kidney Disease Epidemiology
Collaboration Equation [14]. Hypoglycemia in
baseline was identified using an algorithm that
incorporated both diagnostic codes and natural
language processing for clinical notes [15, 16].
Propensity scores were estimated by a logistic
regression model that incorporated potential
predictors of therapy as the independent vari-
ables using treatment EQW versus BI as the
dependent variable. The propensity score model
included a priori-specified confounding vari-
ables and stratification variables so the popula-
tions would remain balanced when conducting
stratified analyses under the assumption that
there was no important interaction between
stratification variables and other covariates.
Clinically important variables were identified
using univariate c-statistics and were forced into
the propensity score model. Other covariates
were allowed to enter the model using a step-
wise selection based on a univariate p value for
entry (p\0.2) and a multivariate p-value for
remaining in the model (p\0.3). The final
propensity score model included several pre-
dictors: demographics (age, sex, race, US region
of residency, calendar year of initiation); health
history (diagnosis indicating the presence or
history of smoking, alcohol abuse, obesity, any
complication of diabetes as a composite and
specifically neuropathy); healthcare utilization
(presence of ER visit, hospitalization, foot
examination, hospitalization days, number of
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medical care sites, number of 3-digit diagnosis
codes, number of procedures, number of medi-
cations, number of antidiabetic medications,
and class of antidiabetic medications (e.g.,
metformin, TZD, SGLT2, DDP-4); and empiri-
cally selected diagnostic codes, procedure codes,
and other medications that had different dis-
tributions of occurrence between EQW and BI
initiators; as well as the potential stratification
variables [age, race, weight, HbA1c, body mass
index (BMI), blood pressure, eGFR, and
hypoglycemia].
Each EQW initiator was matched to up to
two BI initiators using a greedy matching algo-
rithm. Once an EQW initiator was matched
with two BI initiators, the members of the
matched set were removed from subsequent
matching [17, 18]. Cohorts balanced in this
manner may be directly compared for outcomes
since covariate imbalance is addressed by
matching.
Outcome Definitions
Effectiveness
Primary outcomes of treatment effectiveness
included changes from baseline in HbA1c, body
weight, and BMI. For these analyses, the clinical
and laboratory measures were extracted from
the EHR data and summarized in standard
intervals over the first year following initiation
of treatment. HbA1c, weight, and BMI were
summarized in quarterly intervals (3-month
intervals). For these clinical observations and
laboratory measures, the interval value was
taken as the mean of values occurring within an
interval. If no values were observed, then values
were multiply imputed (5 imputations) using
the FCS method. Parameter estimates and
associated variance (standard errors) were
determined within imputed data sets and
pooled (averaged) into a single set of statistics
(SAS PROC MIANALYZE) that reflects the
uncertainty in parameter estimates across all
imputed values.
Tolerability
The primary outcomes used to assess the toler-
ability of the given treatments were the
occurrence of hypoglycemia and gastrointesti-
nal symptoms (nausea, vomiting, diarrhea, and
constipation) in follow-up. Algorithms were
developed to identify events of hypoglycemia
and gastrointestinal symptoms, separately using
both diagnostic codes and natural language
processing of clinical notes.
Using ICD-9 codes within in administrative
diagnostic fields, we identified hypoglycemia
using a modified algorithm described by Ginde
et al. (2008) [19]; we identified gastrointestinal
symptoms using the following ICD-9 codes:
536.2, persistent vomiting; 787.01, nausea and
vomiting; 787.02, nausea alone; 787.03, vom-
iting alone; 787.91, diarrhea; 564.5, functional
diarrhea; and 564.09, constipation. If multiple
events were observed on the same day in an
outpatient setting or within 7 days of a contin-
uous inpatient stay, events were collapsed into a
single event.
The natural language processing (NLP) algo-
rithm processes the syntax of clinical notes to
identify sentiment terms (denial, affirmation) of
the event to enable a determination of whether
the patient/provider is denying or affirming the
occurrence an event. If multiple events were
observed on the same day in an outpatient set-
ting or within 7 days of a continuous inpatient
stay, events were collapsed into a single event.
We included events identified by either the
ICD-9 algorithm or the NLP algorithm. If the
ICD-9 algorithm and NLP algorithm identified
an event on the same day in an outpatient set-
ting or within 7 days during a continuous
inpatient stay, events were collapsed into a
single event.
Analysis Plan
Patient race was identified from the EHR data
and categorized as non-Hispanic white, African
American/other black, or other race/ethnicity.
Patients with unknown race were excluded
from the analysis. All analyses described below
are performed within race strata. Race differ-
ences are indirectly examined referring to the
difference between EQW and BI within the
strata. Each patient was followed from initiation
of new therapy (date of cohort entry) until the
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earliest of the following: occurrence of a new
outcome or event (separately for each event),
disenrollment in the EHR system, or end of the
study follow-up period. Analyses were con-
ducted in an intent-to-treat fashion, with
patients remaining within a single cohort (EQW
or BI) throughout follow-up. The number of
patients and person-time of observation were
used to calculate the proportion and rates of
occurrence of an outcome, respectively. The
distributions of follow-up time were tabulated
for each cohort.
Measurement of Change
For HbA1c, weight, and BMI, change was cal-
culated as the percent difference between the
measured value in the baseline period and
measurements taken in each quarter of the first
year of follow-up. Distributions of changes
across each measure were summarized by pro-
viding the summary statistic (mean, mean per-
cent differences) or the frequency of measures
that were collapsed into a categorical metric.
For mean percent differences, we provide the
estimate and its 95% confidence interval (CI).
Measurement of Occurrence
For hypoglycemia, nausea, vomiting, diarrhea,
and constipation, we evaluated the occurrence
of each event separately. Additionally, we cre-
ated a combined metrics of any nausea or
vomiting, any diarrhea or constipation, or any
GI symptoms. We calculated the frequency of
events and the proportion of each cohort that
experienced the event during follow-up. We
calculated incidence rates of each event (and
95% CI), using person-time censored at first
event during follow-up. Cohorts were compared
using a relative rate (RR) estimate and its 95%
CI.
Further Adjustment for Confounding
The propensity matching of EQW to BI initia-
tors was conducted to achieve balance in
observed covariates between the full cohorts of
BI and EQW initiators, but this balance was not
fully retained within strata of race. For this
reason, measures of change and occurrence
were further adjusted through multivariable
modeling to improve the comparability of EQW
and BI patients within strata of race. For mea-
sures of change and occurrence, mean values,
percentages, and rates were obtained as the least
squared estimates, by cohort and race, from
models adjusted for baseline covariates that
were imbalanced in baseline (linear regression
for means, logistic regression for percentages,
and Poisson regression for rates).
This study protocol and practices were
approved by both privacy and institutional
review boards affiliated with Optum. The study
complies with the Health Insurance Portability
and Accountability Act (HIPAA) guidelines for
the protection of patient confidentiality and
guidelines for good pharmacoepidemiology
practices (GPP).
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
The propensity-matched cohorts included 2008
EQW initiators matched to 4016 BI initiators.
Each cohort had an average follow-up time of
1.5 years. The analyses presented here are lim-
ited to the 1946 EQW initiators and 3903 BI
initiators for whom race was observed. Patient
characteristics are reported by race and drug
cohort (Table 1). Among included patients, 84%
were white, 8% were African American, and 8%
were identified as ‘‘other.’’ The ‘‘other’’ category
included patients identified as Hispanic (65%),
Asian (20%), and multiple races (15%). As a
result of the propensity score matching, no
notable differences were observed between drug
cohorts within strata of race. Differences
between races, however, were observed. As
compared to white patients, African American
and ‘‘other’’ patients were younger and more
likely to be female. Measures of BMI and blood
lipids (with the exception of triglycerides) were
lower in white patients relative to African
American and ‘‘other’’ patients.
Primary measures of effectiveness are repor-
ted by race and drug cohort (Table 2). In addi-
tion to propensity score matching, outcome
measures were adjusted for within-race
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Table 1 Comparison of baseline characteristics between propensity score-matched cohortsa of EQW and BI initiators,
stratiﬁed by race: 1 January 2012 to 31 January 2015, Optum Electronic Health Record Research Database
White Black/African American Other
EQW BI EQW BI EQW BI
1630 3277 151 303 165 323
Age group, n (%)
\34 46 (2.8) 91 (2.8) 7 (4.6) 22 (7.3) 9 (5.5) 15 (4.6)
35–44 153 (9.4) 315 (9.6) 27 (17.9) 50 (16.5) 25 (15.2) 54 (16.7)
45–54 436 (26.7) 862 (26.3) 42 (27.8) 83 (27.4) 46 (27.9) 102 (31.6)
55–64 563 (34.5) 1181 (36.0) 47 (31.1) 99 (32.7) 60 (36.4) 101 (31.3)
65–74 364 (22.3) 707 (21.6) 25 (16.6) 44 (14.5) 23 (13.9) 44 (13.6)
[75 68 (4.2) 121 (3.7) 3 (2.0) 5 (1.7) 2 (1.2) 7 (2.2)
Sex, n (%)
Male 854 (52.4) 1672 (51.0) 47 (31.1) 112 (37.0) 72 (43.6) 145 (44.9)
Female 776 (47.6) 1605 (49.0) 104 (68.9) 191 (63.0) 93 (56.4) 178 (55.1)
Ever smoke, n (%)
No 308 (18.9) 669 (20.4) 56 (37.1) 81 (26.7) 47 (28.5) 76 (23.5)
Yes 1322 (81.1) 2608 (79.6) 95 (62.9) 222 (73.3) 118 (71.5) 247 (76.5)
Alcohol abuse, n (%)
No 1623 (99.6) 3271 (99.8) 150 (99.3) 302 (99.7) 163 (98.8) 321 (99.4)
Yes 7 (0.4) 6 (0.2) 1 (0.7) 1 (0.3) 2 (1.2) 2 (0.6)
HbA1c, n (%)
\7% (53 mmol/mol) 369 (22.6) 663 (20.2) 22 (14.6) 64 (21.1) 24 (14.5) 45 (13.9)
7.1–9%
(54–75 mmol/mol)
808 (49.6) 1604 (48.9) 85 (56.3) 132 (43.6) 79 (47.9) 139 (43.0)
[9 ([54 mmol/mol) 453 (27.8) 1010 (30.8) 44 (29.1) 107 (35.3) 62 (37.6) 139 (43.0)
Any hypoglycemia in baseline, n (%)
No 1562 (95.8) 3157 (96.3) 145 (96.0) 285 (94.1) 150 (90.9) 293 (90.7)
Yes 68 (4.2) 120 (3.7) 6 (4.0) 18 (5.9) 15 (9.1) 30 (9.3)
Any diabetic complication in baselineb, n (%)
No 1309 (80.3) 2621 (80.0) 122 (80.8) 255 (84.2) 120 (72.7) 221 (68.4)
Yes 321 (19.7) 656 (20.0) 29 (19.2) 48 (15.8) 45 (27.3) 102 (31.6)
Clinical measures, mean (SD)
Body mass index 36.87 (0.18) 37.37 (0.13) 38.11 (0.64) 37.18 (0.45) 36.48 (0.58) 34.74 (0.42)
HDL cholesterol 41.66 (0.31) 41.78 (0.23) 49.15 (1.25) 47.69 (1.01) 45.77 (1.11) 44.99 (1.05)
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differences in age, gender, smoking status,
baseline measures (HbA1c, BMI, HDL, LDL),
sulfonylurea use, and number of comorbidities.
With varying degrees of magnitude and statis-
tical significance, the effectiveness measures
were generally more favorable for EQW initia-
tors relative to BI initiators. Among white
patients, HbA1c decreased in the first 6 months
and remained stable (reduction maintained)
through to 1 year. The largest reduction in
HbA1c (measured as a percent change from
baseline) in the EQW group occurred 3–
6 months after initiation (-7.97, 95% CI:
-9.31, -6.63). EQW initiators lost weight
through the 12-month follow-up period. By
9–12 months after EQW initiation, the percent
change in weight was -1.73 (95% CI: -2.45,
-1.02) for white patients, -1.11 (95% CI:
-3.02, -0.81) for African American patients,
and -1.43 (-3.63, -0.77) for ‘‘other’’ patients.
The reductions in HbA1c and weight were sim-
ilar across the race groups. HbA1c reduction was
observed for BI cohorts but no weight reduc-
tion. The proportion of patients achieving any
weight loss in conjunction with maintaining/
achieving HbA1c B7% (53 mmol/mol) was
consistently higher among EQW initiators rel-
ative to BI initiators. At 9–12 months following
initiation, percent change in BMI was most
notable among EQW initiators [-1.77 (95% CI:
-2.49, -1.04) among white patients, -1.19
(95% CI: -3.17, 0.79) among African American
patients, and -1.69 (95% CI: -4.08, 0.70)
among ‘‘other’’ patients]. There was no appre-
ciable change in BMI among BI initiators,
regardless of race.
Unadjusted mean values of HbA1c, weight,
and BMI were compared between races among
EQW initiators (Fig. 1). Measures of weight were
comparable between white and African Ameri-
can patients; however, African American
patients tended to have higher BMIs. White
patients had a lower HbA1c at baseline relative
to African American and ‘‘other’’ patients. This
difference persisted throughout follow-up. In
spite of the variations of point estimates
between races, the changes from baseline in
HbA1c, weight, and BMI followed similar
patterns.
Incidence rates of tolerability indicators are
reported by race and drug cohort, and relative
rates are reported for EQW versus BI within
strata of race (Table 3). Within each race stra-
tum, incidence rates and relative rates were
adjusted for age, gender, smoking status, base-
line measures (HbA1c, BMI, HDL, LDL), and
sulfonylurea use and number of comorbidities.
Among white patients, EQW initiators had an
Table 1 continued
White Black/African American Other
EQW BI EQW BI EQW BI
1630 3277 151 303 165 323
LDL cholesterol 90.93 (0.97) 92.38 (0.65) 99.36 (3.22) 100.53
(2.69)
91.75 (3.04) 92.49 (1.82)
Total cholesterol 170.37
(1.22)
171.17
(0.80)
174.64
(3.76)
175.19
(3.93)
171.07 (3.6) 172.25 (2.54)
Triglycerides 206.02 (3.3) 202.77
(2.36)
134.6 (7.9) 136.91
(6.44)
179.82
(10.33)
189.75
(10.09)
EQW exenatide once weekly, BI basal insulin, SD standard deviation
a The cohorts were balanced on demographic, health utilization, health history, diagnostic and procedure codes, and
medication found to be associated within receipt of EQW compared to BI in propensity score-matched analysis
b Complication of type 2 diabetes mellitu, i.e., renal manifestation (ICD-9: 250.40, 250.42), ophthalmic manifestations
(ICD-9: 250.50, 250.52), neurologic manifestations (ICD-9: 250.60, 250.62), peripheral circulatory disorders (ICD-9:
250.70, 250.72), other speciﬁed manifestations (ICD-9: 250.80, 250.82), unspeciﬁed complication (ICD-9: 250.90, 250.92)
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18% lower rate of hypoglycemia relative to BI
initiators (RR: 0.82 95% CI: 0.66, 1.01). The
association was somewhat more pronounced
among African American patients, among
whom EQW initiators had a 41% lower rate of
hypoglycemia relative to BI initiators (RR: 0.59
95% CI: 0.26, 1.34). While the magnitude of
association between drug cohort and hypo-
glycemia differed, no formal tests were con-
ducted to assess the significance of this
difference. Associations between drug cohort
and individual GI symptoms were comparable
Fig. 1 Measures of weight, HbA1c, and BMI by race among EQW initiators
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between races and as combined outcomes.
Among white and African American patients, GI
symptoms tended to be higher in EQW initia-
tors relative to BI initiators. Due to the limited
sample size, in part, the estimates for African
American and ‘‘other’’ patients were less precise
than those for white patients.
DISCUSSION
Observed measures of tolerability and effec-
tiveness were generally more favorable for EQW
relative to BI, and this finding was comparable
between races. Though no formal tests of sig-
nificance were conducted for between-race
comparisons, EQW appeared to be more
strongly associated with reduced hypoglycemia
incidence in African American patients relative
to white patients. The stronger negative associ-
ation in African American patients was pre-
dominantly driven by an elevated incidence
rate of hypoglycemia among African American
BI initiators. This is consistent with prior
research identifying increased hypoglycemia
risk among African Americans treated with
insulins [10].
The propensity score matching implemented
in this study balances observed confounders
between EQW and BI cohorts. While the dis-
tribution of race was balanced across treatment
groups through propensity score matching,
further multivariable adjustments were made to
improve covariate balance across treatment
within race strata. The multivariable adjust-
ment beyond propensity matching had a mini-
mal impact on the observed measures. No
adjustment or standardization was imple-
mented to attain a balance of covariates
between race groups. As such, apparent differ-
ences in tolerability or effectiveness between
races should not be interpreted as a direct effect
of race, but may be due to differential type 2
diabetes mellitus characteristics present at
baseline. Because this cohort study captures the
real-world differences in risk factors within race,
these comparisons remain informative for the
assessment of expected effectiveness and toler-
ability of EQW by race in a real-world setting.
That is, covariates that are associated with bothT
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race and tolerability or effectiveness should be
viewed as mediators explaining the association
rather than confounders of the association.
The measures of effectiveness and tolerabil-
ity observed in this observational study of
real-world data are generally comparable with
or slightly lower than findings from clinical
trials. In a randomized trial of EQW versus
insulin glargine with 1.6 years of follow-up [20],
the EQW group had an absolute HbA1c decline
from baseline to follow-up of -1.2%. While the
average baseline HbA1c was similar in the trial
(8.3%) and in our study cohorts (8.2% for white
EQW patients and 8.6% African American EQW
patients), the decline seen in the trial popula-
tion was slightly greater than the absolute
declines seen in the first year of this cohort
study, -0.62% and -0.55% for white and Afri-
can American patients, respectively. The weight
loss experienced by EQW users in the trial was
similar to findings within our observational
cohort study. In the trial population, EQW users
lost 2.1 kg of weight compared to 1.9 kg for
white patients and 1.0 for African American
patients in the cohort study. Comparisons
between the trial and our cohort should con-
sider that the trial included a longer follow-up
time for changes in weight and HbA1c
(84 weeks) as compared to our cohort study
(52 weeks). Both studies showed that hypo-
glycemia occurred less often among EQW versus
BI users, yet the detection of hypoglycemia in
trial participants was much greater than in our
study. Specifically among trial participants, 24%
EQW users and 54% insulin glargine users
experienced mild hypoglycemia, yet in the
cohort study accounting for all hypoglycemia
events in the EHR regardless of severity, we
found that among all race groups combined
only 7.4% of EQW and 9.2% of BI initiators
experienced any hypoglycemia in follow-up.
Similarly, nausea occurred more frequently
among EQW users (12%) compared to insulin
glargine users (6%) within 1.6 years of follow-up
compared to 15% vs. 13% among EQW initia-
tors and BI initiators in our cohort study,
respectively.
This study was based on an analysis of EHR
data. This real-word data resource reflects
patient distributions and medical interactions
captured from a geographically diverse set of
hospitals and medical groups. While EHR data
are valuable for examination of clinical health
care outcomes and treatment patterns, data-
bases derived from EHR (such as the one used
for this study) have certain inherent limitations
because the data are collected for the purpose of
clinical patient management, not research.
First, these data represent the intent of the
prescriber through the written prescription for a
medication and do not indicate that a medica-
tion was filled, consumed, or taken as pre-
scribed. This does not alter the interpretation of
the results from a clinical perspective (i.e., out-
comes associated with providing a prescription)
since the non-adherence leading to this form of
misclassification is likely to be representative of
patient populations in a real-word setting. From
a patient perspective (i.e., outcomes associated
with taking the medication), this form of
non-adherence could lead to an underestima-
tion of the incidence of tolerability indicators
(hypoglycemia and GI symptoms) and bias the
observed effectiveness (HbA1c control and
weight change) toward no difference. Clinical
variables are missing for some individuals
because of variation in care practices and
potentially other factors. Additionally, health
care encounters with medical providers who do
not contract with Optum’s EHR services would
not be observed. The observed patient charac-
teristics within this EHR database included a
greater proportion of patients identified as
white relative to national estimates.
To facilitate the uses of EHR data for the
assessment of measures of effectiveness and
tolerability, a multiple imputation method was
implemented to estimate values within stan-
dard intervals of follow-up. Multiple imputa-
tion is founded on the assumption that
unobserved variables are missing at random
(i.e., missingness is random after conditioning
on observed covariates). This assumption is
more broadly applicable than the assumption
that missingness is completely at random (i.e.,
missingness is independent from any covariate,
observed or unobserved), which would mean
the missingness could generally be ignored in
analysis. While multiple imputation reduces the
potential for bias, it is possible that patients
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with observed values are systematically differ-
ent from those with unobserved values in both
unmeasured ways.
CONCLUSION
This retrospective cohort study within a US EHR
database assessed real-world measures of effec-
tiveness and tolerability of EQW relative to BI
within strata of race. Regardless of race, patients
initiating EQW appeared to have better weight
control, larger reductions in HbA1c, and
reduced risk of hypoglycemia relative to BI.
Risks of GI symptoms were modestly elevated
among EQW initiators, though only the
observed difference for nausea in white patients
appears to exclude a chance finding. Measures
of EQW effectiveness and tolerability were
generally comparable between races.
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